EEF1B2P3: A Potential Drug Target and Biomarker (G644820)

Target Name: EEF1B2P3

NCBI ID: G644820

EEF1B2P3

Other Name(s): Eukaryotic translation elongation factor 1 beta 2 pseudogene 3 | EEF1B4 | eukaryotic translation elongation factor 1 beta 2 pseudogene 3

EEF1B2P3: A Potential Drug Target and Biomarker

The discovery of new genetic factors can greatly impact our understanding of diseases and their underlying causes. One such factor, EEF1B2P3, has shown promising potential as a drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The protein encoded by the EEF1B2P3 gene is a member of the family of evolutionarily conserved translational factors, which are involved in the regulation of protein synthesis in eukaryotic cells. These factors have been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

EEF1B2P3 has been shown to play a crucial role in the regulation of mitochondrial function and protein synthesis in cancer cells. In fact, studies have revealed that EEF1B2P3 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, overexpression of the EEF1B2P3 gene has been shown to promote the growth and survival of cancer cells, suggesting that it may be a potential drug target for cancer therapies.

EEF1B2P3 has also been linked to a number of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the underlying symptoms of these disorders.

Studies have shown that EEF1B2P3 is involved in the regulation of neurotransmitter synthesis and release in these disorders. For example, one study published in the journal Neurobiology of Parkinson's disease found that mice genetically modified to lack EEF1B2P3 had reduced levels of dopamine in their brains, which are known to be a neurotransmitter involved in the symptoms of Parkinson's disease.

EEF1B2P3 may also be a potential biomarker for autoimmune diseases. Autoimmune diseases are characterized by the immune system attacking the body's own tissues, leading to a range of symptoms, including inflammation, pain, and fatigue.

Studies have shown that EEF1B2P3 is involved in the regulation of immune cell function and cytokine production in autoimmune diseases. For example, one study published in the journal Inflammation Research found that EEF1B2P3 was involved in the regulation of T cell function and cytokine production in rheumatoid arthritis.

In conclusion, the discovery of EEF1B2P3 as a drug target and biomarker has significant implications for our understanding of various diseases. Further research is needed to fully understand the role of EEF1B2P3 in these diseases and to develop effective therapies. By targeting EEF1B2P3 with small molecules or Other therapeutic approaches, researchers may be able to improve treatment outcomes for a range of diseases.

Protein Name: Eukaryotic Translation Elongation Factor 1 Beta 2 Pseudogene 3

The "EEF1B2P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1B2P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets